The Millennium's Primer Series: Neuroinflammation: The Road to Neuropsychiatric Illnesses.

Gordon, ML, Millennium Health Centers, Inc. Department of Veteran's TBI Recovery. Magnolia, Texas 77354. Neuroendocrinology. This paper was originally presented as a PowerPoint lecture to healthcare at Walter Reed's department of Functional Medicine. April 4, 2023.

Abstract:

Neuroinflammation is a critical factor in the development of neuropsychiatric illnesses, particularly those associated with traumatic brain injury (TBI). Despite advancements in prevention and treatment, TBI remains a significant burden, affecting a substantial portion of the US population. The brain's intricate neurochemistry regulates neuronal activity and relies on precise molecular interactions within cellular and neurotransmitter systems. Even minor disruptions to these interactions can lead to neurological pathology. Recent research has shed light on the role of inflammation in the pathophysiology of trauma, increasing interest in its potential as a mediator of neuropsychiatric conditions. Neurotrauma-induced inflammation is a complex process involving various protein-chemicals, such as cytokines, chemokines, leukotrienes, and interleukins, which can activate microglia—a key component of the central nervous system's immune response. Microglia react to injury rapidly, becoming chronically activated and perpetuating neuroinflammation and oxidative stress that can persist for years after the initial trauma. This chronic inflammation, specifically driven by IL-1β, TNF-α, and NFkB, coincides with the onset of mood and cognitive impairments. Furthermore, the presence of autoantibodies targeting ion channels and neuronal receptors, including N-methyl-D-aspartate receptor (NMDA-R), voltage gated potassium channel complex (VGKC-complex), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R), γ-aminobutyric acid receptor (GABA-R) and dopamine receptor (DR), have been linked to neurological and major neuropsychiatric disorders such as psychosis, major depression, autism spectrum disorders, obsessive-compulsive disorder, and attention-deficit/hyperactivity disorder.

The conventional clinical approach to trauma-related neuropsychiatric disorders has relied on psychotropic medications, but this approach has limitations due to side effects and the lack of inflammatory control. Therefore, a deeper understanding of the role of neuroinflammation in neuropsychiatric illnesses is crucial for the development of more effective and targeted treatment strategies. (272)

Introduction

Traumatic brain injury (TBI) results in external physical forces that mechanically impact the cellular and anatomical structures within the skull. The vulnerable axons spanning the brain, from high-density gray matter to less dense white matter, create a susceptible zone prone to shearing forces. Additionally, the micro- and macro-vasculature are susceptible to damage, leading to vascular tearing and leakage. Within the aftermath of these events, a diverse array of protein-chemicals, including cytokines, leukotrienes, chemokines, and interleukins, are present, initiating the activation of microglia and promoting neuroinflammation and oxidative stress. These processes culminate in the disruption of cellular functioning and physiology, ultimately resulting in neuronal death.

Concomitant with the development of neuroinflammation, driven by specific mediators such as IL-1β, TNF-α, and NFkB, mood and cognitive impairments emerge. The impact of underlying inflammation manifests in various mood disorders, including depression and anxiety, and has been labeled as Post-Traumatic Stress Disorder (PTSD), typically managed with psychotropic medications. However, recent research suggests that the line between neurological and psychiatric illnesses is becoming blurred, as biological abnormalities are increasingly being identified in patients with psychiatric disorders.

Further reinforcing this relationship, a study by Vogelzangs et al. (2012) examined the association between depressive diatheses and inflammatory markers, such as CPR, TNF-α, and IL-6. Surprisingly, they discovered that the levels of these inflammatory markers were higher in individuals using antidepressant medication. Moreover, neuroinflammation has been associated with other psychiatric illnesses such as autism, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADD/ADHD), and depression.

In light of these findings, this review article postulates that secondary trauma, triggered by the primary physical trauma of TBI, induces the release of inflammatory cytokines, leading to the disruption of connectivity between neurons and the interconnected lobes of the brain. It is within this disrupted data streaming between lobes that the root cause of the symptomatology associated with traumatic brain injury is believed to lie. Therefore, exploring the potential use of anti-inflammatory technology holds promise for benefiting TBI patients where traditional psychotropic medications have fallen short.

Setting the Stage: Unraveling the Pathways to Neuroinflammation

Microglia

Microglial cells, constituting approximately 10-12% of the cells in the brain, are primarily found in the grey matter, with particularly high concentrations in regions such as the hippocampus, hypothalamus, basal ganglia, and substantia nigra (Block et al., 2007; Lawson et al., 1990; Mittelbronn et al., 2001). In the healthy adult brain, microglia exist in a "resting" or quiescent state, characterized by a small soma and long, thin processes (ramified) (Hanisch and Kettenmann, 2007). Despite being referred to as "resting," microglia in the intact adult brain are far from dormant. These highly motile cells continuously survey the central nervous system (CNS) microenvironment, with estimates suggesting that they monitor the entire brain parenchyma every few hours (Davalos et al., 2005; Nimmerjahn et al., 2005). Even minor perturbations in CNS homeostasis activate microglia, enabling them to act as the first line of defense during infections, injuries, and diseases.

In response to inflammatory stimuli, microglia undergo rapid activation and morphological changes, characterized by shorter, stouter processes (deramified) and larger soma size (Hanisch, 2002; Hanisch and Kettenmann, 2007; Long et al., 1998). Additionally, activated microglia upregulate cell surface molecules, including major histocompatibility markers (MHC class I and II), receptors for cytokines and chemokines, and other cellular markers indicative of increased reactivity (Lynch, 2009; Perry and **Gordon**, 1988). Microglia can transition from a quiescent state to various activation states in response to different stimuli. The extent of microglial activation depends on the type and duration of the stimulus, the current CNS microenvironment, and exposure to prior and existing stimuli (Perry et al., 2007; Ransohoff and Perry, 2009; Schwartz et al., 2006). Activated microglia release immune mediators that coordinate the response of innate and adaptive immunity, contributing to infection control, debris removal, and tissue repair (Kreutzberg, 1996; Neumann et al., 2009; Streit, 2002).

While microglial activation is necessary for host defense and neuroprotection, excessive or prolonged activation can have detrimental and neurotoxic effects (Block et al., 2007). One proposed mechanism for controlling microglial activation involves their interaction with signaling molecules from neurons. Healthy neurons keep microglia in a resting state through the secretion of soluble factors and membrane-bound signals, including CD200, CX3CL1 (fractalkine), neurotransmitters, and neurotrophins (Biber et al., 2007; Pocock and Kettenmann, 2007). Reductions in these regulatory factors can lead to a reactive microglial phenotype, highlighting the crucial role of neuron-microglia communication in regulating neuroinflammation. Under normal conditions, these neuromodulatory mechanisms effectively regulate neuroimmune responses and restore CNS homeostasis following insults. However, during disease and

injury, excessive or prolonged inflammatory stimulation can disrupt and dysregulate these reciprocal interactions between microglia and neurons. Although aging and stress are not classified as "disease states," they are associated with an enhanced neuroinflammatory environment, which can alter the bidirectional communication between microglia and neurons, resulting in a dysregulated response to immune stimuli.

Astrocytes

Astrocytes, a type of glial cell, are the most abundant cells in the central nervous system (CNS) and play crucial roles in maintaining CNS homeostasis and supporting neuronal function. Prior to activation, astrocytes are in a quiescent state, characterized by a compact cell body with numerous branching processes extending throughout the brain (Matias et al., 2019). In this state, astrocytes perform various functions that contribute to the overall health and proper functioning of the CNS.

Pre-activation, astrocytes fulfill essential roles in regulating neuronal metabolism, providing structural support, and maintaining the blood-brain barrier (BBB). They actively participate in the uptake and recycling of neurotransmitters, particularly glutamate, to prevent excitotoxicity and maintain neurotransmitter balance in the synaptic cleft (Takano et al., 2014). Astrocytes also play a critical role in the regulation of ion and water homeostasis, ensuring optimal neuronal function and signal transmission (Kimelberg, 2010). Moreover, astrocytes contribute to the formation and maintenance of synapses, providing structural support and influencing synaptic plasticity (Allen and Eroglu, 2017).

Astrocytes are also actively involved in the regulation of cerebral blood flow and the maintenance of the BBB. Through their end-feet processes, astrocytes interact with blood vessels and regulate blood flow based on the metabolic demands of neighboring neurons (**Gordon** et al., 2008). They participate in the regulation of endothelial cell tight junctions and the expression of BBB-specific proteins, contributing to the selective permeability of the CNS vasculature (Abbott et al., 2006).

Upon activation, astrocytes undergo profound morphological and functional changes. Reactive astrocytes, also known as astrogliosis, exhibit hypertrophy and increased expression of intermediate filament proteins such as glial fibrillary acidic protein (GFAP) (Liddelow and Barres, 2017). These changes reflect the altered state of astrocytic function during pathological conditions, injury, or neuroinflammatory processes.

Post-activation, reactive astrocytes exhibit a diverse range of functions, both beneficial and detrimental. Reactive astrocytes can release various signaling molecules, including cytokines, chemokines, and growth factors, contributing to the recruitment and activation of other immune cells, and influencing neuronal survival and synaptic plasticity (Sofroniew, 2014). They can also form a glial scar, which helps to contain and isolate damaged areas, preventing the spread of injury (Anderson et al., 2016). Additionally, reactive astrocytes are involved in the clearance of cellular debris and the release of antioxidants to mitigate oxidative stress (Liddelow and Barres, 2017).

However, prolonged, or excessive astrocytic activation can have detrimental effects. Reactive astrocytes can produce pro-inflammatory factors that contribute to neuroinflammation and exacerbate tissue damage (Pekny and Pekna, 2014). They may also display abnormal calcium signaling, impairing their ability to regulate neuronal excitability and synaptic transmission (Giaume et al., 2010). Furthermore, reactive astrocytes can induce the production of extracellular matrix molecules that inhibit axonal regeneration, potentially impeding functional recovery following injury (Sofroniew, 2009).

Astrocytes play critical roles in maintaining CNS homeostasis and supporting neuronal function. In their quiescent state, they regulate neurotransmitter balance, provide structural support, and maintain the BBB.

Upon activation, reactive astrocytes exhibit altered morphology and function, engaging in diverse activities that can both support and impair neuronal health.

Understanding the dynamic functions of astrocytes, both in their quiescent and activated states, is crucial for unraveling their complex contributions to CNS physiology and pathology. While their pre-activation functions are vital for normal neuronal functioning and overall brain homeostasis, their post-activation roles can have significant implications in various neurodegenerative diseases, neuroinflammation, and brain injury.

The dual nature of reactive astrocytes highlights the need for a balanced perspective when considering their effects. On one hand, their ability to release signaling molecules and form glial scars can contribute to tissue repair and protection against further damage. Their involvement in the clearance of debris and release of antioxidants demonstrates their potential for neuroprotection. Furthermore, their influence on synaptogenesis and synaptic plasticity suggests their participation in neural circuit remodeling and functional recovery.

On the other hand, prolonged or excessive activation of astrocytes can lead to detrimental consequences. Their release of pro-inflammatory factors and altered calcium signaling can contribute to chronic neuroinflammation and neuronal dysfunction. The production of inhibitory molecules and disruption of normal synaptic connectivity may hinder the regeneration and repair processes. These aspects highlight the complex interplay between astrocytes, neurons, and other glial cells in various neurological conditions.

Advancing our understanding of astrocytic function in both physiological and pathological contexts is essential for the development of therapeutic strategies. Targeting specific aspects of astrocyte activation, such as modulating their inflammatory response or enhancing their neuroprotective properties, holds potential for therapeutic interventions in neurodegenerative disorders, traumatic brain injury, and neuroinflammatory conditions. Additionally, unraveling the intricate signaling mechanisms between astrocytes and neurons may provide new insights into the pathogenesis of neurological disorders and guide the development of novel therapeutic approaches.

Astrocytes are multifaceted cells that exhibit diverse functions depending on their state of activation. From their roles in neurotransmitter regulation and structural support to their involvement in neuroinflammation and tissue repair, astrocytes have a significant impact on CNS homeostasis and neuronal health. Further investigations into the intricate mechanisms underlying astrocyte function and their interactions with other cells in the CNS are essential for advancing our understanding of neurological diseases and developing effective therapeutic strategies.

Inflammation and Free Radicals

Traumatic inflammation and the generation of free radicals can activate both microglia and astrocytes, triggering a cascade of cellular responses in the central nervous system (CNS). These activated glial cells play critical roles in the neuroinflammatory response following trauma, contributing to both neuroprotective and neurotoxic processes.

In response to traumatic injury, microglia, the resident immune cells of the CNS, rapidly become activated. The release of damage-associated molecular patterns (DAMPs) from injured cells and the disruption of the blood-brain barrier (BBB) lead to the infiltration of peripheral immune cells and the activation of microglia (Loane and Byrnes, 2010). The activation of microglia is characterized by morphological changes, including the retraction of processes and the adoption of an amoeboid-like shape (Hanisch and Kettenmann, 2007). This activation is accompanied by the upregulation of cell surface molecules such as major

histocompatibility complex (MHC) proteins and receptors for cytokines and chemokines (Lynch, 2009). Activated microglia release a range of pro-inflammatory mediators, including cytokines, chemokines, and reactive oxygen species (ROS), exacerbating the inflammatory response, and promoting neuroinflammation (Block et al., 2007).

Similarly, astrocytes also respond to traumatic inflammation and the generation of free radicals. Reactive astrocytosis, characterized by hypertrophy and increased expression of glial fibrillary acidic protein (GFAP), is a hallmark of astrocyte activation following injury (Sofroniew, 2009). Astrocytes can sense and respond to the release of pro-inflammatory cytokines and DAMPs through various receptors, including Toll-like receptors (TLRs) and purinergic receptors (Verkhratsky et al., 2016). The activation of these receptors trigger signaling pathways that lead to the production and release of inflammatory molecules, such as cytokines, chemokines, and ROS (Liddelow and Barres, 2017). Reactive astrocytes also play a role in the regulation of the BBB integrity, as they can release factors that influence endothelial cell tight junctions and contribute to BBB disruption (Abbott et al., 2006).

The activation of microglia and astrocytes in response to traumatic inflammation and free radicals is tightly interconnected. Activated microglia can release cytokines and other signaling molecules that induce astrocyte activation (Pekny and Pekna, 2014). Conversely, reactive astrocytes can release factors that modulate microglial activation and polarization (Liddelow and Barres, 2017). This bidirectional communication between microglia and astrocytes amplifies the neuroinflammatory response, leading to the perpetuation of inflammation and the generation of additional free radicals.

The activation of microglia and astrocytes, while initially serving as a neuroprotective response, can also have detrimental effects on neuronal survival and function. Excessive release of pro-inflammatory molecules and ROS can induce neurotoxicity, disrupt synaptic connectivity, and contribute to secondary neuronal damage following trauma (Sofroniew, 2009). The imbalance between neuroprotective and neurotoxic functions of activated glial cells highlights the complex nature of the neuroinflammatory response in the context of traumatic injury.

Understanding the mechanisms underlying the activation of microglia and astrocytes in response to traumatic inflammation and free radicals is crucial for the development of therapeutic strategies aimed at modulating neuroinflammation and promoting neuroprotection. Targeting the signaling pathways involved in glial activation, such as TLRs and purinergic receptors, holds potential for attenuating the neuroinflammatory response and limiting the detrimental effects of excessive glial activation. By inhibiting these pathways, it may be possible to prevent the release of pro-inflammatory molecules and ROS, reducing neurotoxicity and preserving neuronal function.

Additionally, therapeutic interventions can focus on promoting the neuroprotective functions of activated microglia and astrocytes. Enhancing the secretion of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), by activated glial cells can support neuronal survival and promote tissue repair (Ridet et al., 1997). Modulating the polarization of microglia towards an anti-inflammatory phenotype, characterized by the secretion of anti-inflammatory cytokines and the clearance of cellular debris, may also be beneficial in reducing neuroinflammation and promoting tissue healing (Cherry et al., 2014).

Furthermore, antioxidants and anti-inflammatory agents can be employed to counteract the generation of free radicals and suppress the neuroinflammatory response. These compounds, such as N-acetylcysteine (NAC), quercetin, gamma tocopherol, and minocycline, have shown promising results in preclinical and

clinical studies by reducing glial activation and neuroinflammation (Liu et al., 2019; Cho et al., 2020). Their ability to scavenge free radicals and inhibit the production of pro-inflammatory mediators makes them potential candidates for therapeutic intervention in traumatic brain injury.

Understanding the intricate mechanisms by which microglia and astrocytes are activated in response to traumatic inflammation and free radicals is vital for the development of effective therapeutic strategies. By targeting the signaling pathways involved in glial activation, promoting neuroprotective functions, and employing antioxidants and anti-inflammatory agents, it may be possible to modulate neuroinflammation, mitigate neuronal damage, and facilitate neuroprotection in the aftermath of traumatic brain injury. Further research and clinical studies are needed to elucidate the precise molecular pathways involved and to translate these findings into effective treatments for patients.

Neuroinflammation: Disrupting the Neuropermissive Environment

Neuroinflammation is a complex process characterized by the activation of various immune cells, including microglia and astrocytes, in response to injury, infection, or neurodegenerative diseases. While inflammation is a crucial defense mechanism of the central nervous system (CNS) to maintain tissue homeostasis and initiate repair processes, dysregulated or chronic neuroinflammation can have detrimental effects on neurochemistry and overall brain function.

One of the key consequences of neuroinflammation is the disruption of neurochemistry, which encompasses the intricate balance of neurotransmitters, neuromodulators, and other signaling molecules involved in neuronal communication and regulation. Neurotransmitters such as glutamate, GABA, dopamine, serotonin, and others play critical roles in controlling synaptic transmission, neuronal excitability, and the regulation of mood, cognition, and behavior.

During neuroinflammation, the release of pro-inflammatory cytokines, chemokines, and other immune mediators can perturb the delicate balance of neurotransmitters and their receptors. For example, the release of inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) can lead to increased glutamate release and impaired glutamate reuptake, resulting in excitotoxicity and neuronal damage (Liu et al., 2017). Excitotoxicity, characterized by excessive glutamate signaling and subsequent neuronal death, is implicated in various neurodegenerative disorders and acute brain injuries.

Furthermore, neuroinflammation can affect the availability and function of neurotransmitter receptors, leading to alterations in synaptic transmission and neuronal signaling. Activation of microglia and astrocytes during neuroinflammation results in the release of factors that can modulate the expression and function of neurotransmitter receptors. For instance, increased levels of pro-inflammatory cytokines can downregulate the expression of glutamate receptors, such as the N-methyl-D-aspartate receptor (NMDAR), and impair synaptic plasticity (Viviani et al., 2003). This disruption of glutamate receptor function can contribute to cognitive deficits and memory impairments observed in various neuroinflammatory conditions.

Additionally, neuroinflammation can impact the synthesis and metabolism of neurotransmitters. Inflammatory processes can alter the activity of enzymes involved in neurotransmitter synthesis, such as tyrosine hydroxylase for dopamine or tryptophan hydroxylase for serotonin, leading to imbalances in neurotransmitter levels. These imbalances can contribute to the manifestation of neuropsychiatric symptoms, including depression, anxiety, and cognitive impairments.

Importantly, the disruption of neurochemistry during neuroinflammation is not limited to neurotransmitters alone. Neuroinflammation can also affect the availability and function of neuromodulators, such as brain-

derived neurotrophic factor (BDNF), which plays a crucial role in synaptic plasticity, neuronal survival, and the maintenance of neuronal networks. Dysregulation of BDNF signaling due to neuroinflammation has been implicated in the pathophysiology of several psychiatric and neurodegenerative disorders (Garofalo et al., 2019).

In summary, neuroinflammation has profound effects on neurochemistry, influencing the delicate balance of neurotransmitters, neuromodulators, and their receptors. The disruption of neurochemistry during neuroinflammation can contribute to neuronal dysfunction, excitotoxicity, and the manifestation of various neuropsychiatric symptoms. Understanding the mechanisms underlying these alterations in neurochemistry is essential for developing targeted therapeutic strategies aimed at restoring the balance of neurotransmitters and mitigating the detrimental effects of neuroinflammation on brain function.

Neuroinflammation and Neuropsychiatric Illnesses

Neuroinflammation, characterized by the activation of immune cells and the release of inflammatory mediators within the central nervous system (CNS), has been increasingly recognized as a key contributor to the development and progression of neuropsychiatric conditions. Emerging evidence suggests that chronic neuroinflammation can disrupt normal brain function and contribute to the pathogenesis of various neuropsychiatric illnesses, including mood disorders, schizophrenia, autism spectrum disorders, and cognitive impairments.

Mood Disorders

Neuroinflammation has been strongly implicated in the pathophysiology of mood disorders such as major depressive disorder (MDD) and bipolar disorder. Studies have consistently demonstrated increased levels of pro-inflammatory cytokines, including interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), in the blood and cerebrospinal fluid of individuals with depression (Dowlati et al., 2010). These inflammatory mediators can impact neurotransmitter systems, such as serotonin and dopamine, and disrupt neural circuits involved in mood regulation. Furthermore, chronic neuroinflammation can lead to structural and functional changes in key brain regions implicated in depression, such as the prefrontal cortex and hippocampus.

Post-traumatic stress disorder

PTSD is a psychiatric condition that can occur in individuals who have experienced or witnessed a traumatic event, such as combat, assault, or natural disasters. The chronic activation of the stress response and the associated release of stress hormones can trigger an inflammatory response within the brain. This neuroinflammatory response involves the activation of microglia, the brain's resident immune cells, and the release of pro-inflammatory cytokines and chemokines. These inflammatory mediators can disrupt normal neural circuitry, particularly in regions involved in emotional processing and stress regulation, such as the amygdala, prefrontal cortex, and hippocampus. Neuroinflammation-induced alterations in neurotransmitter systems, such as serotonin and glutamate, may further contribute to the emotional dysregulation and memory disturbances observed in individuals with PTSD. Moreover, neuroinflammation can also impact neuroplasticity and contribute to structural and functional changes in the brain.

Schizophrenia

Neuroinflammation has also been implicated in the pathogenesis of schizophrenia, a severe and debilitating psychiatric disorder characterized by distorted thinking, hallucinations, and impaired social functioning. Postmortem studies have revealed increased microglial activation and elevated levels of pro-inflammatory cytokines in the brains of individuals with schizophrenia (Steiner et al., 2020). The dysregulation of inflammatory pathways can disrupt synaptic connectivity, impair neurotransmitter balance, and contribute to the cognitive and perceptual abnormalities observed in this disorder.

Autism Spectrum Disorders (ASD)

Growing evidence suggests a link between neuroinflammation and the etiology of autism spectrum disorders. Neuroinflammatory processes, including microglial activation and increased cytokine levels, have been observed in postmortem brain tissue of individuals with ASD (Morgan et al., 2010). Disruptions in neurodevelopmental processes mediated by inflammatory mechanisms may contribute to altered neural connectivity, synaptic dysfunction, and the atypical behavioral and social impairments observed in ASD.

Cognitive Impairments

Neuroinflammation can also have profound effects on cognitive function and contribute to the development of cognitive impairment observed in various neuropsychiatric conditions, including Alzheimer's disease and traumatic brain injury (TBI). Inflammation-mediated damage to neurons, synapses, and the blood-brain barrier can disrupt normal cognitive processes, such as learning, memory, and attention. Inflammatory cytokines, such as IL-1β and TNF-α, can impair synaptic plasticity and synaptic transmission, leading to cognitive deficits (Cunningham et al., 2005).

The precise mechanisms by which neuroinflammation leads to neuropsychiatric conditions are still being elucidated. It is likely that the interplay between inflammatory mediators, alterations in neurotransmitter systems, disruption of neural circuits, and structural brain changes collectively contribute to the development and progression of these disorders. Furthermore, genetic and environmental factors may interact with neuroinflammatory processes, increasing susceptibility to neuropsychiatric conditions.

Targeting neuroinflammation as a therapeutic approach has gained considerable attention. Strategies aimed at modulating the inflammatory response, such as anti-inflammatory drugs and nutraceutical products, or immune-modulating agents, have shown promise in preclinical and clinical studies. By attenuating neuroinflammation and restoring the balance of immune responses within the CNS, it is possible to mitigate the pathological consequences and potentially ameliorate symptoms associated with neuropsychiatric conditions.

Furthermore, neuroinflammation plays a significant role in the pathogenesis of neuropsychiatric conditions. The activation of immune cells and the release of inflammatory mediators within the CNS can disrupt normal brain function, leading to mood disorders, schizophrenia, autism spectrum disorders, and cognitive impairments. Chronic neuroinflammation can result in structural and functional changes in key brain regions, neurotransmitter imbalances, and synaptic dysfunction, all of which contribute to the manifestation of these conditions.

Understanding the complex interplay between neuroinflammation and neuropsychiatric illnesses is crucial for the development of effective therapeutic strategies. Targeting the inflammatory pathways involved in glial activation, such as toll-like receptors (TLRs) and purinergic receptors, holds promise for modulating neuroinflammation and promoting neuroprotection. Additionally, interventions aimed at restoring immune homeostasis, such as anti-inflammatory drugs and immune-modulating agents, may offer potential avenues for treatment.

Further research is needed to unravel the intricate mechanisms through which neuroinflammation contributes to the development and progression of neuropsychiatric conditions. By gaining a deeper understanding of the underlying processes, it is possible to identify novel targets for intervention and develop personalized approaches to managing these complex disorders. Ultimately, the goal is to alleviate the burden of neuropsychiatric illnesses and improve the quality of life for affected individuals.

PTSD, the Missed TBI.

Traumatic brain injury (TBI) is a complex condition that can have long-lasting effects on both physical and psychological well-being. In some cases, TBI can progress to the development of post-traumatic stress disorder (PTSD), a psychiatric condition characterized by intrusive thoughts, flashbacks, hyperarousal, and emotional disturbances. The mechanisms underlying the progression from TBI to PTSD are multifactorial and involve both biological and psychosocial factors. Effective management of both the physical and psychological aspects of TBI, including appropriate medical treatment, rehabilitation, and psychological therapies, can help mitigate the risk of developing PTSD. A comprehensive approach that addresses the biological, psychological, and social aspects of the individual's experience is essential in promoting recovery, reducing the burden of PTSD, and improving the overall quality of life for individuals affected by TBI.

Following a TBI, there are several biological processes that can contribute to the development of PTSD. Neuroinflammation, which occurs as a result of the initial brain trauma, can persist, and disrupt normal neural circuitry involved in emotional regulation and stress response. The release of pro-inflammatory cytokines, activation of microglia, and oxidative stress can lead to neuronal damage, alterations in neurotransmitter systems, and changes in neuroplasticity, all of which may contribute to the development of PTSD symptoms.

Additionally, the psychological impact of experiencing a traumatic brain injury can also contribute to the progression to PTSD. The trauma itself, along with the physical, cognitive, and emotional consequences of the injury, can trigger a cascade of psychosocial factors that increase the risk of developing PTSD. These factors include the severity of the injury, the individual's perception of the event, previous exposure to trauma, pre-existing mental health conditions, and the availability of social support.

Furthermore, the presence of other co-occurring conditions commonly associated with TBI, such as depression, anxiety disorders, and sleep disturbances, can further complicate the progression to PTSD. These conditions often interact with each other, exacerbating symptoms and creating a complex clinical picture.

Conclusion.

The research and understanding of neuroinflammation and its implications have shed light on its significant role in various aspects of brain health and disease. Neuroinflammation, characterized by the activation of glial cells and the release of inflammatory mediators, plays a pivotal role in the pathogenesis of neurological disorders such as traumatic brain injury (TBI) and neuropsychiatric conditions. It is clear that the activation of microglia and astrocytes in response to traumatic inflammation and free radicals can have both beneficial and detrimental effects on neuronal health. While these glial cells are essential for maintaining central nervous system homeostasis, their dysregulation and prolonged activation can contribute to neuroinflammation, oxidative stress, and neuronal damage.

Traumatic brain injury, with its complex cascade of events, provides a compelling example of how neuroinflammation can lead to a range of neurological and psychiatric sequelae. The disruption of neurochemistry, neuroplasticity, and neurotransmitter systems due to neuroinflammation contributes to the development of various neuropsychiatric conditions, including mood disorders, schizophrenia, and cognitive impairments. Furthermore, neuroinflammation has been identified as a potential factor in the pathogenesis of post-traumatic stress disorder (PTSD), where the chronic activation of stress responses and subsequent inflammatory processes can contribute to emotional dysregulation and memory disturbances.

Recognizing the intricate mechanisms involved in neuroinflammation and its association with neuropsychiatric conditions opens avenues for therapeutic interventions. Targeting the signaling pathways and molecular mechanisms involved in glial activation, such as toll-like receptors (TLRs) and purinergic receptors, holds promise for modulating neuroinflammation and promoting neuroprotection. Anti-inflammatory nutraceuticals, immune-modulating agents, and interventions aimed at restoring immune homeostasis are being explored as potential strategies to mitigate the detrimental effects of neuroinflammation.

In summary, neuroinflammation serves as a crucial link between brain health, injury, and neuropsychiatric conditions. By unraveling the intricate mechanisms underlying neuroinflammation, we can pave the way for innovative therapeutic strategies that target inflammation, promote neuroprotection, and ultimately improve the lives of individuals impacted by neurological disorders and psychiatric illnesses. The obvious and utmost goal is to end the cycle of suicides occurring subsequent to TBI and over-medication. FIN.

References.

1. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-69.
2. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387-1394.
3. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009; 27:119-145.
4. Streit WJ. Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history. Front Aging Neurosci. 2010; 2:22.
5. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10(4):217-224.
6. Heneka MT, Carson MJ, Khoury JE, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405.
7. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol. 2012;33(3):315-327.
8. Beumer W, Gibney SM, Drexhage RC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol. 2012;92(5):959-975.
9. Kohman RA, Rhodes JS. Neurogenesis, inflammation, and behavior. Brain Behav Immun. 2013;27(1):22-32.
10. Wohleb ES, Franklin T, Iwata M, et al. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. 2016;17(8):497-511.
11. Steiner J, Frodl T, Schiltz K, et al. Innate immune cells and C-reactive protein in acute stress and development of depressive symptoms: a longitudinal study. J Psychiatr Res. 2011;45(6):788-793.
12. Khandaker GM, Pearson RM, Zammit S, et al. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71(10):1121-1128.
13. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34.
14. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18(2):206-214.
15. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
16. Gattaz WF, Abrahão AL, Foccacia R, et al. Serum antibodies to BSA and LPS in major depression. J Affect Disord. 1995;33(2):113-119.
17. Zandi PP, Belmonte PL, Willour VL, et al. Association study of Wnt signaling pathway genes in bipolar disorder. Arch Gen Psychiatry. 2008;65(7):785-793.
18. **Najjar S, Pearlman** DM, Devinsky O, Najjar A, Zagzag D. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation. 2013; 10:142.
19. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Mol Psychiatry. 2016;21(12):1696-1709.
20. Kéri S. Genes for psychosis and creativity: a promoter polymorphism of the neuregulin 1 gene is related to creativity in people with high intellectual achievement. Psychol Sci. 2009;20(9):1070-1073.
21. Steiner J, Frodl T, Schiltz K, et al. Innate immune cells and C-reactive protein in acute stress and development of depressive symptoms: a longitudinal study. J Psychiatr Res. 2011;45(6):788-793.
22. Khandaker GM, Pearson RM, Zammit S, et al. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71(10):1121-1128.
23. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34.
24. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18(2):206-214.
25. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
26. Gattaz WF, Abrahão AL, Foccacia R, et al. Serum antibodies to BSA and LPS in major depression. J Affect Disord. 1995;33(2):113-119.
27. Zandi PP, Belmonte PL, Willour VL, et al. Association study of Wnt signaling pathway genes in bipolar disorder. Arch Gen Psychiatry. 2008;65(7):785-793.
28. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696-1709.
29. Kéri S. Genes for psychosis and creativity: a promoter polymorphism of the neuregulin 1 gene is related to creativity in people with high intellectual achievement. Psychol Sci. 2009;20(9):1070-1073.

30. **Eric C. Meyers**, Bleyda R. Solorzano, Justin James, Patrick D. Ganzer, Elaine S., Robert L. Rennaker, M. P. K. and S. H. (2018). Neurotoxic reactive astrocytes are induced by activated microglia. *Physiology & Behavior*, *176*(1), 100–106. https://doi.org/10.1038/nature21029.Neurotoxic

A Short Biography

Dr. Mark L. Gordon, specializing in Endocrinology since 1995, has devoted his career to understanding and treating the effects of traumatic brain injuries (TBIs). Having personally experienced multiple TBIs without loss of consciousness, he encountered the limitations of traditional treatment approaches. Driven by his own journey towards recovery, he delved into medical literature, seeking answers to the root causes of his condition and those affecting other post-concussion patients.

Dr. Gordon discovered that hormonal deficiencies, though initially evident, were merely surface manifestations of a more intricate cascade of biochemical changes triggered by trauma, particularly neuroinflammation. Recognizing the importance of addressing both inflammation and hormonal imbalances, including neurosteroids and neuroactive steroids, he pioneered a comprehensive approach that resulted in accelerated recoveries without reliance on conventional therapies.

In 2004, Dr. Gordon transitioned his expertise to the field of Neuroendocrinology, applying his knowledge to all cases of symptomatic TBI. However, it was in 2009 that his focus shifted towards the needs of the military community, driven by the alarming rise in mental health issues, depression, and suicides among veterans. A pivotal moment came with the successful treatment of Army Special Forces Sergeant First Class Andrew Marr, who experienced remarkable recovery from multiple blast wave traumas. Through Dr. Gordon's intervention, Marr was able to discontinue multiple medications, reunite with his family, pursue an MBA, and co-author a book that inspired the award-winning film "Quiet Explosions."

To date, Dr. Gordon and Mr. Marr have extended their groundbreaking protocol, known as the Millennium's protocol, to over 1200 veterans. Their work is carried out through the Millennium and Warrior Angels Foundations (501c3), providing financial support and a non-toxic treatment program that has yielded significant success. With a commitment to transforming the lives of veterans, Dr. Gordon and his team strive to make a lasting impact and offer hope through their innovative approach.

The Millennium Health Centers, Inc., is a self-funding organization that derives financial support for our Veterans' Program from the sale of our proprietary products at www.MillenniumHealth**Store**.com . Educational materials for our products Clear Mind & Energy, Brain Care 2, B is for Brain, Brain Rescue 1, Brain Rescue 3, and Secretropin/Dynatropin can be obtain from our education TBI site: www.TBIHelpNow.org . If you want a discount code, please use Phase2022 at check out. Make sure you are a subscriber to the **Store** for any checkout discount codes to work.